During the past decade, Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa) conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 5 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)" #1 sponsor was "Cycle Pharmaceuticals Ltd." with 3 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Fertin Pharma A/S" with 2 trials sponsored, "Actavis Inc." with 1 trials sponsored and "Reig Jofre Group" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)" #1 collaborator was "Parexel" with 3 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)" are "Hereditary Tyrosinemia, Type I" (3 trials), "Healthy" (2 trials), "Smoking Cessation" (2 trials), "Allergy" (1 trials) and "Healthy Volunteers" (1 trials). Many other conditions were trialed in "Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)" in a lesser frequency.

Most popular intervention types in "Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)" are "Drug" (9 trials). Other intervention types were less common.

The name of intervention was led by "Nitisinone" (3 trials), "Nicotine lozenge" (2 trials), "Orfadin" (2 trials), "Budesonida Pulmictan® 200 µg" (1 trials) and "Budesonide 200 µg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), 9 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".